Literature DB >> 11096692

Parkinson's Disease: Motor Fluctuations.

.   

Abstract

Motor fluctuations represent important late complications of Parkinson's disease treated with levodopa. Although treatment of these problems has improved with the emergence of numerous pharmacologic and surgical therapies, the various options can make it confusing. Pharmacologic treatment is the first step. Polytherapy is often the rule in this case with a variety of agents available as adjunctive therapy with levodopa. These adjuncts include dopamine agonists (bromocriptine, pergolide, pramipexole, ropinirole), catechol-O-methyltransferase (COMT) inhibitors (tolcapone), controlled-release formulations of levodopa, monoamine oxidase (MAO) B inhibitors (selegiline), and amantadine. The treatment can consist of any of a number of combinations of these agents. No single algorithm can be used in all patients; therapy should be individualized. Physicians treating these patients need to be well versed in late complication patterns as well as the medications chosen. In addition, optimal doses vary, and often patients are considered treatment failures and taken off medications before reaching that level. In the more complicated cases, patients should be evaluated by specialists in movement disorders. With this in mind, some guidelines are offered for the pharmacologic approach to patients with fluctuating responses to medications. For simple wearing off, controlled-release levodopa (Sinemet CR, Dupont Pharmaceuticals, Wilmington, DE), COMT inhibitors, MAO inhibitors, and dopamine agonists are reasonable options. For more complicated fluctuations, dopamine agonists with limits on levodopa are the first choice, especially when dyskinesia is present; when dyskinesia is not a factor, COMT inhibitors may be used. For dyskinesia specifically, dopamine agonists or addition of amantadine can be helpful. Surgery should be a treatment of last resort for patients in whom medical therapy fails. Patients who are candidates for medial pallidotomy should be fluctuators with severe dyskinesia and "off" periods that have not improved with pharmacologic therapy. Thalamic deep brain stimulation (DBS) should be used only in patients with tremor-predominant disease and severe intractable tremor that is unresponsive to medication and occurs not only at rest but with posture and action as well. Surgical therapy should be performed only in centers with surgeons experienced in stereotactic techniques and movement disorder specialists to ensure that the appropriate patients come to surgery and that complications are kept to a minimum. Dietary adjustment has a limited role in treating advanced Parkinson's disease.

Entities:  

Year:  1999        PMID: 11096692     DOI: 10.1007/s11940-999-0029-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  34 in total

1.  High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease.

Authors:  R Pahwa; S Wilkinson; D Smith; K Lyons; E Miyawaki; W C Koller
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

2.  A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.

Authors:  J M Cedarbaum; M Hoey; F H McDowell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

3.  Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

Authors:  L Verhagen Metman; E R Locatelli; D Bravi; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

4.  A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.

Authors:  A Lieberman; C W Olanow; K Sethi; P Swanson; C H Waters; S Fahn; H Hurtig; M Yahr
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

5.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.

Authors:  L Verhagen Metman; P Del Dotto; P van den Munckhof; J Fang; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

6.  Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.

Authors:  G Fabbrini; M M Mouradian; J L Juncos; J Schlegel; E Mohr; T N Chase
Journal:  Ann Neurol       Date:  1988-09       Impact factor: 10.422

7.  The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way.

Authors:  J C Stoof; J Booij; B Drukarch; E C Wolters
Journal:  Eur J Pharmacol       Date:  1992-03-31       Impact factor: 4.432

8.  Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

9.  Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.

Authors:  A H Rajput; W Martin; M H Saint-Hilaire; E Dorflinger; S Pedder
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

10.  Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.

Authors:  P Limousin; P Krack; P Pollak; A Benazzouz; C Ardouin; D Hoffmann; A L Benabid
Journal:  N Engl J Med       Date:  1998-10-15       Impact factor: 91.245

View more
  1 in total

1.  Identification of target areas for deep brain stimulation in human basal ganglia substructures based on median nerve sensory evoked potential criteria.

Authors:  F Klostermann; J Vesper; G Curio
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.